The molecule of the title compound, C 9 H 9 N 5 O, is approximately planar (the r.m.s. deviation of all non-H atoms is 0.08 Å ). The amine substituent is pyramidal at the N atom. An intramolecular N-H hydrazine Á Á ÁO C hydrogen bond is present. In the crystal, molecules are connected via N-HÁ Á ÁN and N-HÁ Á ÁO hydrogen bonds, forming infinite layers parallel to (010). This polymorph is triclinic, space group P1, whereas the previously reported form was monoclinic, space group P2 1 /c [Elgemeie et al. (2013) . Acta Cryst. E69, o187], with stepped layers and a significantly lower density.
Related literature
Synthetic purine (Hamad & Derbala, 2001 ) and pyrazole (Elgazwy, 2003; Madkour & Elgazwy, 2007) analogues find numerous applications in clinical medicine and medical research. For the synthesis, chemistry, medicinal chemistry and biological activity of related compounds, see: Elgazwy et al. (2012a Elgazwy et al. ( ,b, 2013 ; Arnost et al. (2010) . For the monoclinic polymorph of the title compound, see: Elgemeie et al. (2013 Elgemeie et al. ( , 2014 . For a description of the Cambridge Structural Database, see: Allen (2002).
Experimental
Crystal data Table 1 Hydrogen-bond geometry (Å , ). 
Comment
Synthetic purine (Hamad & Derbala, 2001 ) and pyrazole (Elgazwy, 2003; Madkour & Elgazwy, 2007) analogues find numerous applications in clinical medicine and medical research. As part of our work directed towards the synthesis of pyrazolones (Elgazwy et al., 2012a (Elgazwy et al., , 2012b , we have recently reported various successful approaches to the syntheses of pyrazolone analogues that are interesting for biochemical reactions. The title compound (Z)-3-amino-4-(2-phenylhydrazono)-1H-pyrazol-5(4H)-one (I) was prepared in the course of these investigations.
By chance, compound I was also prepared and structurally investigated during a collaboration with a different group (Elgemeie et al., 2013 (Elgemeie et al., , 2014 ; regrettably, the stereochemistry was erroneously described as E). The current structure proved to be a different polymorph of I, being triclinic (space group P1; henceforth It) rather than monoclinic (space group P2 1 /c; henceforth Im).
The molecule of It is shown in Fig. 1 . Molecular dimensions, such as the bond lengths C4═N4 1.3070 (10) and N4-N5 The molecules of It are connected by hydrogen bonds (Table 1) to form infinite layers (one per b translation) parallel to the ac plane (Fig. 2 ). There are two three-centre interactions (N5-H05···O1 intra-and intermolecular, N1-H01···N1/N2) and two two-centre interactions involving the NH 2 H atoms (with N2 and O1 as acceptors). In Im, one of the N3 H atoms forms a three-centre system with N1 and N2, the N5-H05···O1 interaction is purely two-centre, N1-H01 and N3-H03A are two-centre donors to O1. The packing of Im is a stepped layer structure that intuitively seems to display a less efficient packing than that of It; consistent with this are the crystallographic densities of 1.464 and 1.491 g cm -3
, respectively, but we have carried out no further calculations or experiments to test this hypothesis.
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Experimental
The title compound was obtained according to the following general procedure (Arnost et al., 2010) 
Refinement
The NH H atoms were refined freely. Other H were placed in calculated positions and refined using a riding model with C-H arom 0.95 Å; the hydrogen U values were fixed at 1.2 × U(eq) of the parent atom for these H.
Computing details
Data collection: CrysAlis PRO ( 
Figure 1
The molecule of the title compound in the crystal; ellipsoids represent 50% probability levels.
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Figure 2
Packing diagram of the title compound viewed perpendicular to the ac plane. Phenyl rings are reduced to the ipso carbons for clarity. Intramolecular hydrogen bonds are drawn as thin and intermolecular hydrogen bonds as thick dashed lines; the latter are numbered according to their order in the relevant Table. H bonds #4 are omitted because they represent the weak components of asymmetric three-centre interactions.
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